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Abstract
Loss of the chromatin remodeling ATPase CHD5 has been linked to the progression of neuroblastoma tumors, yet the
underlying mechanisms behind the tumor suppressor role of CHD5 are unknown. In this study, we purified the human
CHD5 complex and found that CHD5 is a component of the full NuRD transcriptional repressor complex, which also contains
methyl-CpG binding proteins and histone deacetylases. The CHD5/NuRD complex appears mutually exclusive with the
related CHD4/NuRD complex as overexpression of CHD5 results in loss of the CHD4 protein in cells. Following a search for
genes that are regulated by CHD5 in neuroblastoma cells, we found that CHD5 binds to and represses the G2/M checkpoint
gene WEE1. Reintroduction of CHD5 into neuroblastoma cells represses WEE1 expression, demonstrating that CHD5 can
function as a repressor in cells. A catalytically inactive mutant version of CHD5 is able to associate with a NuRD cofactor but
fails to repress transcription. Our study shows that CHD5 is a NuRD-associated transcriptional repressor and identifies WEE1
as one of the CHD5-regulated genes that may link CHD5 to tumor suppression.
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Introduction
Chromodomain helicase DNA binding protein 5 (CHD5) is a
chromatin remodeling factor and a member of the SNF2-like
family of ATPases [1–4]. CHD5 is preferentially expressed in the
vertebrate nervous system and disruption of its expression levels
leads to neural tube defects in mice [5,6]. In adults, expression of
CHD5 is frequently lost in a variety of cancers either due to
deletions of chromosome 1p36.3 [7–9] or due to CHD5 promoter
CpG-hypermethylation [10,11]. Loss of CHD5 is correlated with a
poor prognosis in neuroblastoma tumors, and neuroblastoma cells
that express CHD5 are more responsive to treatment than those
that do not express CHD5 [12]. Similarly, low expression of
CHD5 in pancreatic cancers correlates with lower survival
following chemotherapy [13].
While the links between CHD5 and cancer progression are
rapidly emerging, the role of CHD5 in cells remains poorly
understood. CHD5 is most closely related to the widely expressed
chromatin remodeling ATPase CHD4 (also known as Mi-2beta),
which is a subunit of the Nucleosome Remodeling and
Deacetylase (NuRD) complex [14–17]. The NuRD complex
contains two catalytic activities, ATP-dependent chromatin
remodeling and histone deacetylation, and is generally involved
in repressing transcription (reviewed in [18]). The CHD4-
containing NuRD complex consists of the CHD4 ATPase, the
histone deacetylases HDAC1 and 2, the histone-binding proteins
RbAP46/48, the methyl-CpG-binding domain proteins MBD2 or
MBD3, p66a and p66b (also known as GATAD2A and
GATAD2B), and the metastasis-associated (MTA) proteins
MTA1, MTA2, and MTA3. While the precise distribution of
subunits across NuRD complexes is not well understood, multiple
complexes have been shown to exist that contain some combina-
tion of the core subunits. For example, NuRD complexes have
been isolated that contain either MBD2 or MBD3 but not both
[19].
In contrast to CHD4, little is known about the interacting
partners and cellular role of CHD5. CHD5 from rats has been
shown to interact with some subunits of the NuRD complex,
suggesting that CHD5 may also be part of a NuRD-like complex
and, therefore, repress transcription [20]. In addition, CHD5 was
reported to be enriched at promoters of specific genes, further
supporting a role for CHD5 in transcriptional regulation
[5,20,21]. Whether CHD5 is part of a full NuRD complex in
human cells and whether its ATPase activity is required to regulate
transcription has not been shown. It is also unclear why cells of the
sympathetic nervous system express both CHD4 and CHD5, but
recent evidence indicates that these proteins may play distinct
functions. A study characterizing the chromatin remodeling
activity of CHD5 found it remodels nucleosomes through a
distinct unwrapping activity that is not readily observed for CHD4
[4]. Whether the differences in the cellular roles of CHD4 and
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CHD5 remodel nucleosomes or whether they reflect other,
unknown features of the two ATPases is still not known. In this
study, we found that CHD5 interacts with the full NuRD complex
in human cells and appears to compete with CHD4 for
incorporation into the complex. We also found that CHD5
represses transcription of WEE1, in both neuroblastoma and
pancreatic cancer cell lines. Moreover, the CHD5 protein can be
detected at the WEE1 promoter in pancreatic cancer cells that
express endogenous CHD5. Finally, a mutant version of CHD5
that is unable to remodel chromatin can associate with other
NuRD subunits but does not fully repress WEE1 transcription. In
summary, our study shows that human CHD5 functions as a bona
fide transcriptional repressor and identifies a CHD5-dependent
transcription pathway in cancer cells.
Materials and Methods
Analysis of the CHD5/NuRD complex
The cDNAs of CHD5 (Open Biosystems) and CHD4 (DF/
HCC DNA Resource Core) were subcloned into pOZ-N, which
expresses the cDNAs as FLAG/HA N-terminal fusions [22]. HeLa
S3 cell lines that stably express pOZ-N-CHD5 were generated,
and CHD5 complexes were purified by tandem affinity purifica-
tion as described [22–24]. The purified material was analyzed by
mass spectrometry at the Blais Proteomics Center at the Dana-
Farber Cancer Institute in order to identify co-purifying factors.
The list of potential binding partners was filtered to remove
proteins identified with a frequency.1% across a large set of
negative control TAPs. In addition, we required that at least one
peptide of the reported protein partner could be matched
unambiguously to a single gene [25].
Protein interactions were confirmed by anti-FLAG co-immu-
noprecipitation followed by western blotting. HEK293T-derived
Phoenix A cells grown in 10 cm dishes were transiently transfected
by CaPO4 [22] with the empty pOZ-N vector, or pOZ-N
containing the human cDNA for CHD4 (pOZ-N-CHD4), wild-
type CHD5 (pOZ-N-CHD5), or mutant CHD5 (pOZ-N-
mutCHD5). Two days after transfection, the cells were collected,
washed with 1X PBS, and lysed in Lysis Buffer [20 mM Tris-Cl,
pH 7.6, 0.15 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1%
Triton X100, 1 mM DTT, 0.2 mM PMSF, 0.5 mM benzami-
dine]. The insoluble material was pelleted by centrifugation, and
the extract was pre-cleared by incubation with IgG Sepharose 6
(GE Lifesciences) for 1 hour followed by a brief centrifugation to
remove the resin. A sample of the extract was saved and the
remainder of the extract was incubated with anti-FLAG resin
(Sigma) for 3 hours. The resin was pelleted and washed three times
with Lysis Buffer, and the proteins eluted in NuPage Sample
Buffer (Life Technologies). An aliquot of the initial extract and the
immunoprecipitated samples were resolved by SDS-PAGE.
Western blotting was carried out using the following commercial
antibodies: anti-CHD4 (SAB4200107; Sigma), anti-CHD5 (sc-
271248; Santa Cruz Biotech.), anti-MTA2 (PA1-41581, Thermo
Sci.), anti-HDAC1 (sc-7872, Santa Cruz Biotech.), anti-RbAP46/
48 (4633, Cell Signaling Tech.), anti-MBD3 (sc-9402, Santa Cruz
Biotech.), and anti-histone H3 (4499, Cell Signaling Tech.).
Nuclear and pellet extracts were prepared as previously
described [26,27] from PANC-1 cells that stably express pOZ-
N-CHD5 or pOZ-N-mutCHD5. Briefly, isolated nuclei were
resuspended and incubated for 30 min in a high-salt buffer
containing 20 mM Hepes-K+, pH 7.6, 0.42 M KCl, 1.5 mM
MgCl2, 20% glycerol, 0.2 mM EDTA, 1 mM DTT, and then
centrifuged at 160006g for 15 min to pellet the insoluble material.
The pellet was resuspended by Dounce homogenization in a buffer
containing 20 mM HEPES-K+, pH 7.6, 5 mM MgCl2, 20%
glycerol, 0.2 mM EDTA, 1 mM DTT, and 1 mM CaCl2. The
extract was then incubated with MNase (1 u/ml; Worthington) for
30 min at room temp, and centrifuged at 160006g to remove any
remaining insoluble material. The supernatant was collected and
the volume adjusted so that the final volumes of the soluble and
pellet extracts were the same. An equal aliquot was used in western
blotting with the indicated antibodies and scanned using an
Odyssey scanner (LiCor).
Chromatin immunoprecipitation (ChIP)
Anti-CHD5 rabbit polyclonal antibodies were generated against
a bacterially-expressed, recombinant fragment of CHD5 that is
not conserved with other remodeling factors (Covance Research).
Crosslinked chromatin was made by treating PANC-1 [35] and
KELLY [34] cells with 1% formaldehyde for ,30 min followed
by nuclei extraction and sonication [30]. A sample of the soluble,
crosslinked chromatin was uncrosslinked, deproteinized and
resolved by agarose gel electrophoresis. Average DNA fragments
were ,700 bp. The concentration of the soluble chromatin was
estimate by A260 and 140 ug of chromatin was used per IP with
40 mg of anti-CHD5 serum, pre-immune serum or anti-pol II
antibodies (05-952, Millipore). The antibody-bound fragments
were precipitated, uncrosslinked, and the DNA fragments purified
as described [28]. Quantitative PCR of the WEE1 locus or distal
sites were performed in quadruplicate reactions using a SYBR
green mix (Thermo). The primers used for the ChIP analyses are
listed in Table S1. The ChIP assays were each performed at least
three independent times. The enrichment values were calculated
using the 2-ddCt comparing bound v. input or bound (antibody) v.
bound (pre-immune) with normalization to a distal intergenic locus
of chromosome 1.
Quantitative RT-PCR
HEK293T-derived Phoenix A cells were grown in 10 cm dishes
in DMEM (with 10% FBS/1% pen-strep) and transiently
transfected by CaPO4. For the assay to monitor the levels of
CHD4 protein, 0, 2, 5, 10, or 15 mg of pOZ-N-CHD5 DNA were
transfected, and the empty pOZ-N plasmid was co-transfected (15,
13, 10, 5, 0 mg, respectively) so that the total amount of DNA in
each transfection totaled 15 mg. After two days, the cells were
harvested and split into two. Half of the cells were used to make
whole cell extracts for western blotting (as described above) and
the other half of the cells were used to extract total RNA using the
RNeasy kit (Qiagen) with a DNaseI digestion step. For the assays
used to monitor WEE1 expression, we transfected approximately
0, 5, and 15 mg of the pOZ-N-CHD5 with co-transfection of the
empty pOZ-N plasmid as described above. The KELLY cells were
grown in RPMI (with 10% FBS/1% pen-strep) and transfected
with 15 mg of pOZ-N-CHD5 using Lipofectamine 2000 (Life
Technologies). The transfection efficiency of the KELLY cells
varied, and was monitored by parallel transfection assays using a
beta-gal reporter. PANC1 cells were grown in DMEM (with 10%
FBS/1% pen-strep) and transfected with a scrambled, nontarget-
ing control siRNA (IDT) or siRNAs that target human CHD5 [set
2:GCAUGUCAACGGGAAGUACAGCACC; set 6:AGUGUA-
AAGGGAAGCGGAAGAAGAA (IDT)].
The microarray analysis of KELLY cells transiently transfected
with pOZ-N or pOZ-N-CHD5 was performed at the DFCI
Microarray Core Facility using Human Gene 1.0 ST Arrays
(Affymetrix). The raw data have been deposited and are publically
available at NCBI [GEO Accession: GSE59899].
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with M-MuLV reverse-transcriptase (New England Biolabs) and
SYBR FAST qPCR mix (Kapa Biosystems). The primer-sets to detect
CHD5 transcripts were: Forward 5’- TGCTTAAAGGAGCC-
CAAGTC, Reverse 5’-TTGGTCAGCGTGTGGTAATC. The
CHD4 primer-sets were based on those previously published
(CHD4 set 1 in [29]). Standard curves were performed using these
two primer-sets with CHD4 and CHD5 cDNAs to ensure
comparable amplification efficiencies and no cross-amplification.
The 5S rDNA transcript was used as an internal control with
primer-sets previously reported [30]. The values from the quanti-
tative RT-PCR assays were compared using the 2‘-ddCT method.
For the cell viability assay, KELLY cells were transfected with
pOZ-N or pOZ-N-CHD5. Two days after transfection, the cells
were counted and re-plated (Day 0) in media containing 2 mM of
a WEE1 inhibitor (Cat: 681641, EMD Millipore) for an additional
two days. The media was changed to fresh media with inhibitor
and the cell viability was estimated on the indicated days using
CellTiter-Glo (Promega).
Results and Discussion
Human CHD5 is a subunit of the full NuRD complex
To explore the role of CHD5 in cells, we purified the native
CHD5-containing complex from a human cell-line and identified
the binding partners of CHD5. For this analysis, we established a
HeLa S3 cell line that stably expresses a FLAG/HA-tagged copy
of human CHD5 and purified the CHD5 complex by tandem
affinity purification. We then identified the CHD5-associated
proteins by mass spectrometry [22,31,32]. Enrichment analysis
[33] revealed that the set of 122 proteins that specifically co-purify
with CHD5 is strongly enriched for GO-terms associated with the
NuRD complex (log odds ratio 2.4, Padj,0.001). We found that
the core members of the NuRD transcriptional repressor complex,
with the exception of CHD4, were present in the FLAG/HA-
CHD5 complex, including MTA1, MTA2, MTA3, HDAC1,
HDAC2, MBD2, MBD3, RbAP46/48, and p66a/b (Figure S1).
These results are consistent with the findings of Potts et al. [20],
but also suggest that CHD5 and CHD4 might associate with
NuRD in a mutually exclusive manner. To confirm the interaction
between CHD5 and the subunits of the NuRD complex, we
transiently transfected a HEK293T-derived cell line, which
expresses endogenous CHD4, with plasmids expressing either
FLAG-tagged CHD5 or FLAG-tagged CHD4. Following trans-
fection, the epitope-tagged proteins were immunoprecipitated
from whole-cell extracts, and the co-precipitating factors were
analyzed by western blotting (Figure 1A). We found that both
CHD4 and CHD5 interact with the same set of NuRD subunits
but do not associate with each other, as no CHD4 was detected in
the CHD5-containing complex isolated from HeLa cells or
following immunoprecipitation of CHD5 from transiently trans-
fected HEK293T-derived cells.
The finding that both CHD5 and CHD4 interact with the same
set of cofactors suggests that these two enzymes might compete for
interaction with the complex in cells that express both proteins. To
test this hypothesis, we overexpressed CHD5 by transiently
transfecting HEK293T-derived cells with increasing amounts of
a CHD5 expression plasmid or an empty vector, and monitored
the levels of CHD4 protein by western blotting. We found that
overexpression of CHD5 results in an almost complete loss of
CHD4 protein in cells, while the levels of HDAC1, a core member
of the NuRD complex, remain unaltered (Figure 1B). Thus, the
NuRD complexes in these cells appear to convert from CHD4-
containing to CHD5-containing. To determine whether the
reduction in the levels of CHD4 protein following overexpression
of CHD5 is due to silencing of the CHD4 gene, we measured the
CHD4 mRNA levels by quantitative RT-PCR. Following
transfection of the CHD5 cDNA, we found that the levels of
CHD4 mRNA increased slightly, indicating the reduction in
CHD4 is not due to inhibition of CHD4 transcription (Figure 1C).
We believe that the loss of CHD4 observed upon CHD5
overexpression is due to the competition between CHD4 and
CHD5 for binding to the NuRD complex, which could result in
exclusion of CHD4 from the complex, leading to its instability.
CHD5 represses transcription of WEE1
The interaction of CHD5 with the NuRD complex suggests that
CHD5 might be involved in transcriptional repression. It also
raises the possibility that loss of CHD5 during neuroblastoma
progression disrupts specific transcriptional pathways involved in
cell growth. To identify a candidate gene regulated by CHD5, we
reintroduced CHD5 in a neuroblastoma cell line and performed
pilot microarray analyses. For this study we chose KELLY cells
[34], which we found do not express CHD5 and have a higher
efficiency of transfection (,30%) when compared with other
neuroblastoma cell lines. We transfected KELLY cells with a
control vector or a vector containing the human CHD5 cDNA
and, two days after transfection, compared the expression levels of
multiple genes using microarrays. The raw data have been
deposited at NCBI [GEO Accession: GSE59899]. We then
identified the genes that showed changes in their expression levels
following CHD5 expression. We found that the cell-cycle regulator
WEE1 was one of the genes that showed the most significant
change in expression following the transfection of CHD5 (Figure
S2). To validate this result, we repeated the transient transfection
experiments and performed quantitative RT-PCR (qRT-PCR)
using primers that amplify the WEE1 mRNA or, as a control, the
Figure 1. CHD5 co-purifies with the NuRD transcriptional
repressor complex. (A) FLAG-tagged CHD4 and CHD5 were
immunoprecipitated from a transiently transfected HEK293T-derived
cell line, and the samples were analyzed by western blotting using the
indicated antibodies. The empty vector was also transfected in parallel
[Control]. (B) The HEK293T-derived line was transiently transfected with
increasing amounts of the CHD5-expression plasmid. An empty vector
was included where necessary to keep the final amount (15 mg) of
transfected plasmid constant. Following transfection, cell extracts and
RNA were prepared to measure CHD4 levels by western blotting and
CHD4 and CHD5 mRNA levels by qRT-PCR.
doi:10.1371/journal.pone.0108066.g001
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analysis, the levels of the WEE1 transcript consistently decrease by
30–40% following reintroduction of CHD5 (Figure 2A). We
believe that the reduction in WEE1 transcription might have
been even higher if the transfection efficiency of KELLY cells
could be improved. It should also be noted that under our
transfection conditions, the mRNA and protein levels of CHD4 do
not change significantly, suggesting that expression of CHD5 in
these cells is not sufficient to destabilize CHD4 (Figure S3A).
To further confirm that CHD5 expression leads to a decrease in
WEE1 mRNA, we repeated the transient transfection experiments
using the HEK293T-derived cell line, which does not express
CHD5 and has a higher efficiency of transfection than the KELLY
cells. We transfected two different amounts of the CHD5
expressing plasmid into the cells and observed that the levels of
CHD5 transcripts increased as more plasmid was transfected. We
then analyzed the levels of WEE1 transcripts and found that
transfection of the CHD5-expressing plasmid reduced the levels of
WEE1 transcript. Further, the levels of WEE1 transcripts in cells
with high levels of CHD5 expression drop to approximately 10%
of control transfected cells (Figure 2B). The almost complete loss
of WEE1 transcripts was only observed when we obtained very
high transfection efficiencies, as lower levels of CHD5 transfection
repress WEE1 expression to a lesser degree. We should note that
we cannot rule out the possibility that high levels of CHD5
expression could lead to other off-target effects that may
contribute to the loss of WEE1 expression. Nonetheless, using
two cell lines, which do not have detectable levels of endogenously
expressed CHD5, we have found that reintroduction of CHD5
leads to transcriptional repression of the candidate gene WEE1.
Next, we decided to further explore the connection between
WEE1 and CHD5 in cells that express CHD5 endogenously. For
this analysis, we used the pancreatic cancer cell line PANC-1 [35],
which expresses CHD5 at levels readily detectable by qRT-PCR
and western blotting. We performed siRNA knockdown experi-
ments to reduce the levels of CHD5 in these cells and then
compared the levels of WEE1 transcripts in the CHD5-
knockdown cells to those in cells treated with a scrambled, control
siRNA. We found that reducing the levels of CHD5 in the PANC-
1 cells leads to a significant increase in WEE1 transcripts
(Figure 2C). It should be noted that our transient knockdown of
CHD5 does not significantly affect the levels of CHD4 protein
(Figure S3B). Taken together, our experiments, which use three
different cell types, have shown that human CHD5 can act as a
transcriptional repressor and that WEE1 is one its target genes.
The WEE1 protein is an integral component of the G2/M
checkpoint regulatory network. In normal cells, WEE1 is a ser/thr
kinase that phosphorylates cyclin-dependent kinase 1 (CDK1;
reviewed in [36]). Phosphorylation of CDK1 inhibits its activity
and blocks entry into mitosis. It has been reported that some
cancer cells, including neuroblastoma, have elevated levels of the
WEE1 protein [37,38]. The mechanism that ties WEE1 expres-
sion to cancer growth is not well understood, although it has been
suggested that WEE1 can act as an oncogene by blocking DNA
damage-induced apoptosis [39]. In the case of neuroblastoma
tumors, maintaining high levels of WEE1 is essential for survival,
as studies have shown that neuroblastoma cells are sensitive to
inhibitors of WEE1 [38].
CHD5 is bound to the WEE1 promoter
As mentioned above, CHD5 could either directly regulate the
transcription of WEE1 or could indirectly affect its expression by
regulating other transcription factors that, in turn, modulate the
expression of WEE1. To determine whether WEE1 is a direct
target of CHD5, we performed chromatin immunoprecipitation
(ChIP) analyses of CHD5 in PANC-1 cells, which express
endogenous CHD5. To identify the region corresponding to the
WEE1 promoter, we performed ChIP using anti-RNA polymerase
II (pol II) antibodies, followed by quantitative PCR using sets of
primers that span the 5’ end of the WEE1 locus and the ZNF143
gene, which is approximately 115 kb upstream of WEE1
(Figure 3A). We observed an enrichment of fragments near the
5’ end of WEE1 and ZNF143, indicating that these regions do
contain the promoters of these two genes (Figure 3B). We then
performed the ChIP analysis using anti-CHD5 antibodies and also
Figure 2. CHD5 expression leads to repression of WEE1. (A) The
neuroblastoma line KELLY or (B) 293T-derived cells were transiently
transfected with vector (vec.) or the vector containing the human CHD5
cDNA. In the case of the 293T-derived cells, two amounts of CHD5
cDNA were transfected (see Methods). Two days after transfection, the
cells were harvested and total RNA was prepared. Quantitative RT-PCR
was performed to monitor the levels of the CHD5 and WEE1 transcripts.
The values shown are normalized to a 5S rRNA housekeeping transcript.
(C) CHD5 levels were reduced siRNA-mediated knockdown in PANC-1
cells. As a control (ctrl), a scramble siRNA was transfected in parallel. The
levels of CHD5 protein were detected by western blotting (left) and the
levels of WEE1 mRNA were analyzed by qRT-PCR. Error bars represent
SD [n=3].
doi:10.1371/journal.pone.0108066.g002
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WEE1 gene (Figure 3C) but not at regions flanking the promoter
or at the ZNF143 promoter. We also did not observe significant
enrichment of promoter sequences when pre-immune sera were
used, or when anti-CHD5 antibodies were used in KELLY cells
(i.e., CHD5-deficient; Figure 3D). The enrichment of CHD5 at
the WEE1 promoter in PANC-1 cells implicates WEE1 as a direct
target for endogenously expressed CHD5.
A catalytically-inactive mutant CHD5 fails to repress
transcription
CHD5 is part of the SNF2-like family of helicase-related protein
and was recently shown to be an ATP-dependent chromatin
remodeling factor [4]. To determine whether the remodeling
activity of CHD5 is required for its ability to repress transcription,
we analyzed a catalytically-inactive mutant version of CHD5 (mut
CHD5). The mut CHD5 contains a two amino acid substitution in
the conserved Walker B motif (Figure 4A, top), which is required
for ATP hydrolysis. We have previously shown that mut CHD5
does not hydrolyze ATP or remodel chromatin [4].
To first determine whether mut CHD5 associates with the
NuRD complex, we transiently transfected the HEK293T-derived
cells with constructs that express FLAG-tagged copies of wild-type
or mut CHD5, and immunoprecipitated the CHD5 proteins using
anti-FLAG antibodies (Figure 4A, bottom). We then performed
western blotting against one of the NuRD subunits, RbAP46/48.
Both wild-type and mut CHD5 proteins interact with RbAP46/
48, suggesting that the chromatin remodeling activity of CHD5 is
not required to incorporate CHD5 into the complex.
Next, we investigated whether mut CHD5 is able associate with
chromatin in cells. In general, CHD5 is poorly extracted from
nuclei using traditional high salt (i.e., 0.42 M KCl) extraction
methods. In order to fully extract CHD5 from cells, the insoluble
material that remains following high salt extraction needs to be
homogenized and digested with micrococcal nuclease to release
the chromatin-bound proteins. To determine whether mut CHD5
has similar chromatin association properties as wild-type CHD5,
we stably transfected PANC-1 cells with the FLAG-tagged wild-
type or mut CHD5 constructs and prepared nuclear and
solubilized pellet extracts from the cells (Figure 4B). We then
performed western blotting of the extracts and found no significant
difference in the extractability of wild-type and mut CHD5
proteins. While some wild-type and mut CHD5 proteins were
observed in the high-salt soluble extract, most of the wild-type and
mut CHD5 protein was in the MNase digested pellet fraction. As
controls, we performed western blotting for the replication protein
A subunit, RPA1, which is evenly distributed between soluble and
pellet extracts, and histone H3, which is almost exclusively found
in the pellet fraction. This finding, along with the observation that
mut CHD5 is likely incorporated into the NuRD complex,
suggests that the two-amino acid substitution in the mut CHD5
protein does not lead to gross changes in its solubility or
conformation.
To determine whether the ATPase activity of CHD5 is required
to repress transcription of WEE1, we transiently transfected
Figure 3. CHD5 is enriched at the WEE1 promoter. (A) Schematic of the WEE1 locus with the putative WEE1 promoter and direction of
transcription indicated. The promoter of the ZNF143 gene is approximately 115 kb upstream of WEE1. The horizontal bars depict the location of
primersets used. (B) ChIP experiments using anti-RNA pol II antibodies show enrichment of RNA pol II at both WEE1 and ZNF143 promoters. ChIP
experiments using anti-CHD5 sera indicate the enrichment of CHD5 at the WEE1 promoter but not the ZNF143 promoter. As a negative control, ChIP
experiments using pre-immune sera (pre-IgG) were performed and show no specific enrichment patterns. Values shown indicate bound v. input
signals normalized to a distal intergenic region. (C) As a negative control, ChIP experiments were performed using anti-CHD5 sera and chromatin
from KELLY cells (CHD5-negative). No enrichment was observed at the WEE1 promoter using KELLY cells. Error bars represent SD [n=3].
doi:10.1371/journal.pone.0108066.g003
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constructs, extracted RNA from the transfected cells, and
performed a qRT-PCR analysis as described above (Figure 4C).
We measured the levels of CHD5 transcripts from the transfected
plasmids, as well as the endogenous levels of WEE1 mRNA and
the 5S rRNA control. We found that, unlike wild-type CHD5, the
mut CHD5 was unable to repress transcription of WEE1,
suggesting that the chromatin remodeling activity is required for
the regulation of at least a subset of CHD5-dependent genes. The
mechanism by which the ATP-dependent chromatin remodeling
activity of CHD5 represses transcription is currently unknown. In
general, many chromatin remodeling factors act to increase the
accessibility of DNA to DNA-binding proteins. It is possible that
the remodeling activity of CHD5 helps load the NuRD cofactors
onto the DNA. CHD5 may accomplish this by unwrapping
nucleosomes to allow binding of the NuRD subunits that possess
DNA binding activities (e.g., MBDs or MTAs) or to expose the
underlying histones to the histone binding subunits (e.g., HDACs
and RbAP46/48). Another possibility is that the chromatin
remodeling activity of CHD5 serves to enhance the binding of
CHD5, which serves as a hook to lock the NuRD complex onto
chromatin. We have previously shown that the affinity of CHD5
for mononucleosomes is significantly higher in the presence of
ATP than in the presence of non-hydrolyzable AMP-PNP,
suggesting that CHD5 remains tightly associated with remodeled
nucleosomes. Thus far, we have not able to generate viable cell
lines that stably express mut CHD5 at levels that are sufficient
CHIP analysis and, therefore, we have been unable to determine
whether the mut CHD5 binds the WEE1 promoter.
The fact that the mut CHD5 is no more enriched in the high-
salt nuclear extracts than wild-type CHD5 suggests that the
activity of CHD5 may not be required for the binding of CHD5-
NuRD complexes at every target. The presence of DNA and
histone-binding subunits in the NuRD complex may play a major
role in binding to most sites across the genome, while the activity
of CHD5 may be required for only a subset of loci. If true, this
model could shed light on the reason why cells like the precursor
cells of the peripheral nervous system need both CHD4-NuRD
and CHD5-NuRD complexes. Because the cofactors for CHD4
and CHD5 appear to be identical, the differences in the two
complexes may reside exclusively with CHD4 and CHD5. Both
CHD4 and CHD5 contain histone-binding chromodomains and
PHD fingers, which may target CHD4 and CHD5 to distinct
chromatin domains in the cell. Studies on the histone-binding
properties of the chromodomains and PHD fingers of CHD4 and
CHD5 have not shown clear differences between them but those
studies are ongoing (e.g., see [40–42]). It is also possible that
CHD4 and CHD5 have distinct remodeling activities and that
some feature of neural-cell chromatin is resistant to the remodeling
activity of CHD4. This model is consistent with our previous
Figure 4. A catalytically inactive mutant CHD5 does not repress transcription. (A) Top, the mutant version of CHD5 (mut CHD5) contains a
two-amino acid substitution in the Walker B motif of the ATPase domain. FLAG-tagged [F] wild-type and mut CHD5 expressing plasmids were
transiently transfected into 293T-derived cells. Bottom, the CHD5 proteins were immunoprecipitated with anti-FLAG antibodies and the samples
analyzed by western blotting against CHD5 or the NuRD subunit RbAP46/48. (B) Soluble, high-salt nuclear extracts or chromatin pellet extracts were
prepared from stably transfected PANC-1 cells and used in western blotting assays with antibodies against the FLAG tag, the replication protein A
subunit RPA1, or core histone H3. (C) Quantitative RT-PCR analysis of WEE1 transcripts after transfection of wild-type or mut CHD5. The expression of
wild-type and mut CHD5 were also analyzed using primers against the transfected CHD5. The values were normalized to the 5S rRNA housekeeping
transcript. Error bars represent SD [n=3].
doi:10.1371/journal.pone.0108066.g004
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possess the robust nucleosome unwrapping activity observed with
CHD5 [4]. This is true despite the fact that CHD4 possesses a
high specific activity in other remodeling assays [4]. Thus, the
remodeling activity of CHD5 may facilitate the binding of the
NuRD complex to sites with unusual structural features or patterns
of histone and DNA modification.
In addition to demonstrating that CHD5-NuRD complexes
exist in human cells and that CHD5 represses transcription, we
also identified WEE1 as a CHD5-dependent gene. Whether or not
the tumor suppressor role of CHD5 is linked to WEE1 expression
is not fully clear. WEE1 acts to inhibit the cell cycle and
derepression of WEE1 expression upon loss of CHD5 should
enhance the G2/M checkpoint. However, the fact that WEE1
appears to act as an oncogene in several cancers, including
neuroblastoma, suggests that restricting entry into mitosis is an
important step during tumor progression. Slowing entry into
mitosis likely gives the dividing cells adequate time to complete S-
phase and repair any DNA lesions [39]. This regulation becomes
increasingly important when cells acquire MYCN amplification,
which accelerates cell growth [43]. In normal cells, CHD5 acts as
a tumor suppressor that is dependent on other pathways involved
in cell-growth, such as p16 and p19 [7]. For example, induced
expression of CHD5 in normal MEFs leads to a reduction in cell
proliferation [21]. Whether CHD5 is required to regulate the
levels of WEE1 in the context of normal cell growth is not clear.
On the other hand, loss of CHD5 in cancer cells may provide a
selective advantage by allowing the cells to elevate their levels of
WEE1 expression. The fact that neuroblastoma cells have elevated
levels of WEE1 and are sensitive to WEE1 inhibitors [38] supports
this model. Expression of CHD5 in the neuroblastoma cells was
previously shown to limit cell growth, although the effects were
modest [21]. Similarly, we found that transient expression of
CHD5 in KELLY cells can combine with a WEE1 inhibitor to
further limit cell viability (Figure S4).
It is surprising that in the context of cells that have lost CHD5,
the presence of the related factor, CHD4 does not appear to
adequately compensate for the loss of CHD5. While it is possible
that CHD4 and CHD5 have some overlapping activities, the
presence of CHD4 in neuroblastoma cells suggests that the overlap
is limited. It also implies at least some separation of function of the
CHD4 and CHD5-containing NuRD complexes.
Supporting Information
Figure S1 Mass spectrometry results of the factors
present in the CHD5-containing complex that was
purified by tandem affinity purification from HeLa
cells. The number of unique peptides for each factor is listed.
(TIF)
Figure S2 Top hits from the microarray analysis of
KELLY cells transiently transfected with vector or a
CHD5 cDNA. The fold change represents the signal from the
CHD5 transfected cells divided by the signal from the cells
transfected with the vector. CHD5 and WEE1 (highlighted in
gray) were validated by qRT-PCR. The raw data are accessible at
NCBI [GEO Accession: GSE59899].
(TIF)
Figure S3 (A) Transient expression of CHD5 at low levels in
Kelly cells does not significantly affect CHD4 protein or transcript
levels. (B) siRNA-mediated knockdown of CHD5 in PANC-1 cells
does not affect CHD4 protein levels. The replication protein A
subunit, RPA2 was used as a control.
(TIF)
Figure S4 Combining transient expression of CHD5 in
KELLY cells with a WEE1 inhibitor reduces cell growth.
KELLY cells were transiently transfected with vector or the
CHD5 cDNA and incubated with a WEE1 inhibitor. The relative
cell count was determined by measuring the cell viability at the
indicated days divided by the starting cell viability at day 0. Data
are represent mean and SD [n=3].
(TIF)
Table S1 Sequences of the primers used in the ChIP
analyses.
(DOC)
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